Under construction – not a live service
Sign in
Not yet taking people in ChinaPhase 2

Moving people with obesity from semaglutide to zovaglutide, a safety study

Tests safety of changing from semaglutide to zovaglutide in obesity.

Plain-language title generated from the registry record
Registry title: A Study Evaluating Safety and Tolerability of Switching From Semaglutide to Zovaglutide in Adults With Obesity (HORIZON-SWITCH-SZ)

Key facts

Where
Beijing, Changchun, Changde, Chengdu, Handan, Harbin, Huizhou, Jinan, Jincheng, Langfang, Nanyang, Shenyang, Yichang, and Zibo, ChinaSee the 16 sites
Phase
Phase 2

AI summary: who the study is looking for

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults aged 18 to 75 with obesity (BMI 28 kg/m² or more) to test the safety of switching from semaglutide to zovaglutide.

Age
18 to 75 years
Sex
Men and women can join.
Disease stage
Obesity with a BMI of 28 kg/m² or more at screening.
Earlier treatment
Weight change from diet and exercise alone in the 3 months before screening was not more than 5%. People who used medicines or treatments that affect weight in the 3 months before screening cannot join.

Main reasons for not taking part

  • Obesity caused by a single gene change, another disease or medicines
  • Diabetes, or HbA1c 6.5% (48 mmol/mol) or more, or fasting blood glucose 7.0 mmol/L (126 mg/dL) or more
  • History of pancreatitis or pancreatic injury
  • Personal or family history of medullary thyroid carcinoma (MTC) or MEN2
  • PHQ-9 score of 15 or more, or suicidal thoughts or behaviour on screening questionnaires

Read by machine on 9 November 2026.

Could this be for you?

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 75 years old?

Source: NCT07812597, who can take part

Where in China

  • Beijing Friendship Hospital, Capital Medical UniversityBeijing, ChinaNo longer taking part
  • Peking University People's HospitalBeijing, ChinaNo longer taking part
  • Jilin Province FAW General HospitalChangchun, ChinaNo longer taking part
  • The First People's Hospital of ChangdeChangde, ChinaNo longer taking part
  • The 2nd People's Hospital of ChengduChengdu, ChinaNo longer taking part
  • Handan First HospitalHandan, ChinaNo longer taking part
  • Harbin Medical University Affiliated Fourth HospitalHarbin, ChinaNo longer taking part
  • Huizhou Central People's HospitalHuizhou, ChinaNo longer taking part
  • Central Hospital Affiliated to Shandong First Medical UniversityJinan, ChinaNo longer taking part
  • Jincheng General HospitalJincheng, ChinaNo longer taking part
  • Hebei Petro China Cental HospitalLangfang, ChinaNo longer taking part
  • The First Affiliated of Nanyang Medical CollegeNanyang, ChinaNo longer taking part
  • The Fifth People's Hospital of ShenyangShenyang, ChinaNo longer taking part
  • Yichang Central People's Hospital (Xiling Campus)Yichang, ChinaNo longer taking part
  • Zibo Central hospitalZibo, ChinaNo longer taking part
  • Zibo Municipal HospitalZibo, ChinaNo longer taking part

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?
Print a page for my doctor

Trial details

Who runs it
Beijing QL Biopharmaceutical Co.,Ltd
Trial code
NCT07812597
Record updated
10 September 2026
Original description
The main purpose of this study is to evaluate the safety and tolerability of continuing treatment with zovaglutide injection following titration to 2.4 mg semaglutide injection in adult participants with obesity.Read full original descriptionShow less

A Multicenter, Randomized, Active-Controlled, Open-Label Phase IIb Study Evaluating Safety and Tolerability of Switching to Zovaglutide Injection After Titration to 2.4 mg Semaglutide Injection (Wegovy®) in Adults With Obesity (HORIZON-SWITCH-SZ)

The main purpose of this study is to evaluate the safety and tolerability of continuing treatment with zovaglutide injection following titration to 2.4 mg semaglutide injection in adult participants with obesity.

Inclusion: Male or female subjects aged≥18years and≤75 years at the time of signing the Informed Consent Form (ICF); At screening, Body Mass Index (BMI)≥28kg/m²; Weight change due to diet and exercise alone within 3 months prior to screening did not exceed 5%.

Exclusion: Previously diagnosed obesity caused by monogenic mutations, other diseases, or medications; Used of medicines or treatments that affect weight within 3 months prior to screening; History of acute or chronic pancreatitis, or pancreatic injury; History of medullary thyroid carcinoma (MTC) or type 2 multiple endocrine neoplasia (MEN2) in personal or family history; History of medullary thyroid carcinoma (MTC) or type 2 multiple endocrine neoplasia (MEN2) in personal or family history; Previous diagnosis of diabetes; or HbA1c ≥ 6.5% or fasting blood glucose ≥ 7.0 mmol/L at screening; Patient Health Questionnaire-9 (PHQ-9) scale score is ≥ 15 at screening; Screening Columbia-Suicide Severity Rating Scale(C-SSRS) questionnaire suicide ideation response of "Category 4 or 5," or any "yes" response to suicidal behavior questions.

ClinicalTrials.gov NCT07812597